GE Healthcare CTO joins PhoreMost board
PhoreMost, a Cambridge biopharma company dedicated to drugging ‘undruggable’ disease targets, has appointed Dr Lorenz Mayr to its board as a non-executive director.
Dr Mayr is chief technology officer at GE Healthcare Life Sciences, where he is responsible for R & D strategy and innovation across all life sciences business areas.
His experience in drug discovery and development, and specifically his expertise in functional genetic screening in target identification, will help drive the expansion of PhoreMost’s next-generation SITESEEKER® target discovery platform and guide the development of the company’s drug discovery programme.
He has extensive global experience in pharmaceutical R & D, including holding positions as vice-president & global head at AstraZeneca and executive director at Novartis Pharmaceuticals and Bayer Pharmaceuticals.
Dr Mayr gained his PhD at the University of Bayreuth in Biochemistry and Biophysics, subsequently completing his PostDoc at the M.I.T/Whitehead Institute in Cambridge, US.
PhoreMost CEO Dr Chris Torrance said: “Lorenz’s expertise and global industry leadership will be invaluable in shaping PhoreMost’s future development as a fully integrated target identification and drug discovery company. As a key thought leader in functional screening and novel modalities we are particularly proud to welcome him to our board.”
Dr Mayr added: “The convergence of biology and technology is an innovative and industry-changing area which opens the door to identify many new drug targets and improved therapies, not previously seen with conventional methods.
“Such is the potential of the company’s SITESEEKER platform that I am extremely pleased to join the PhoreMost board at a pivotal stage in the company’s development.”